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Abstract
Background:  Duloxetine hydrochloride is a reuptake inhibitor of 5-hydroxytryptamine and
norepinephrine used to treat depression, generalized anxiety disorder, neuropathic pain, and stress
incontinence in women. We investigated the efficacy of duloxetine in painful diabetic neuropathy
and fibromyalgia to allow comparison with other antidepressants.
Methods: We searched PubMed, EMBASE (via Ovid), and Cochrane CENTRAL up to June 2008
for randomised controlled trials using duloxetine to treat neuropathic pain.
Results: We identified six trials with 1,696 patients: 1,510 were treated with duloxetine and 706
with placebo. All patients had established baseline pain of at least moderate severity. Trial duration
was 12 to 13 weeks. Three trials enrolled patients with painful diabetic neuropathy (PDN) and
three enrolled patients with fibromyalgia. The number needed to treat (NNT) for at least 50% pain
relief at 12 to 13 weeks with duloxetine 60 mg versus placebo (1,211 patients in the total
comparison) was 5.8 (95% CI 4.5 to 8.4), and for duloxetine 120 mg (1,410 patients) was 5.7 (4.5
to 5.7). There was no difference in NNTs between PDN and fibromyalgia. With all doses of
duloxetine combined (20/60/120 mg) there were fewer withdrawals for lack of efficacy than with
placebo (number needed to treat to prevent one withdrawal 20 (13 to 42)), but more withdrawals
due to adverse events (number needed to harm (NNH) 15 (11 to 25)). Nausea, somnolence,
constipation, and reduced appetite were all more common with duloxetine than placebo (NNH
values 6.3, 11, 11, and 18 respectively). The results for duloxetine are compared with published
data for other antidepressants in neuropathic pain.
Conclusion: Duloxetine is equally effective for the treatment of PDN and fibromyalgia, judged by
the outcome of at least 50% pain relief over 12 weeks, and is well tolerated. The NNT of 6 for 50%
pain relief suggests that this is likely to be a useful drug in these difficult-to-treat conditions, where
typically only a minority of patients respond. Comparing duloxetine with antidepressants for pain
relief in DPN shows inadequacies in the evidence for efficacy of antidepressants, which are
currently recommended in PDN care pathways.
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Background
Neuropathic pain is the consequence of damage to the
central nervous system (e.g. cerebrovascular accident,
multiple sclerosis or spinal cord injury) or peripheral
nervous system (e.g. painful diabetic neuropathy (PDN),
postherpetic neuralgia (PHN), surgery). It has a signifi-
cant negative impact on quality of life [1]. Some patients
with neuropathic pain respond well to treatment and oth-
ers show no obvious response [2-4]. No pharmacological
intervention produces meaningful relief for more than
half the patients with neuropathic pain [5].
The incidence of PHN and trigeminal neuralgia and PDN
together is almost 0.1% per year in the UK [6]. The inci-
dence of neuropathic pain is growing, presumably
because of increased numbers of older persons and dia-
betics, amongst whom about one in five develop painful
neuropathy at some stage. Neuropathic pain is quite com-
mon in general medical practice with about 1% point
prevalence in UK if fibromyalgia, PDN, PHN, and trigem-
inal neuralgia are included [7].
The most common pharmacological approaches to the
management of neuropathic pain include antidepressants
(tricyclic antidepressants, serotonin and norepinephrine
reuptake inhibitors), antiepileptics (valproate, car-
bamazepine, gabapentin, pregabalin), opioids, other
analgesics, topical lidocaine patch, and topical capsaicin.
The evidence for these has been reviewed extensively [4,8-
16].
5-hydroxytryptamine (5HT) and norepinephrine (NE) are
involved in the modulation of endogenous analgesic
mechanisms via descending inhibitory pain pathways in
the brain and spinal cord [17]. Disinhibition and imbal-
ance of 5HT and NE in endogenous pain inhibitory path-
ways could contribute to persistent pain. An increase in
5HT and NE may increase inhibition of painful signals,
improving pain relief.
Duloxetine hydrochloride is a serotonin-norepinephrine
reuptake inhibitor used to treat depression, generalized
anxiety disorder, neuropathic pain, and stress inconti-
nence in women. We investigated the efficacy of duloxet-
ine in the management of PDN and fibromyalgia as
duloxetine had not been included in the most recent sys-
tematic reviews, including one of antidepressants [13].
Duloxetine in PDN alone has been the subject of a recent
post hoc analysis [18].
Methods
We searched PubMed, EMBASE (via Ovid), and Cochrane
CENTRAL up to June 2008 for randomised controlled tri-
als using duloxetine to treat neuropathic pain. The
detailed search strategy included use of the drug name
"duloxetine" anywhere in an article, together with "rand-
omized controlled trial" as subject heading, publication
type or text word; this was modified appropriately for dif-
ferent databases. Reference lists of retrieved articles and
reviews were also searched for relevant trials. We con-
tacted Boehringer Ingelheim Limited as a UK distributor
for duloxetine in neuropathic pain to enquire about rele-
vant published or unpublished studies, and examined an
on-line register [19].
Included trials had to be randomised, double blind, pla-
cebo controlled, and use duloxetine to treat adult patients
with painful neuropathies of any cause. Trials had to have
a minimum of 10 patients per treatment arm, and a
planned duration of at least four weeks.
The abstracts were read, and potentially useful reports
retrieved in full. No information was taken from posters
or abstracts. Decisions on inclusion or exclusion of trials,
assessment of trial quality and validity and all data extrac-
tion were made independently by three reviewers, with
discrepancies resolved by consensus.
Methodological quality of included studies was assessed
using a validated 5-point scale [20] utilising reporting of
randomisation, blinding, and withdrawals. The maxi-
mum score possible was 5 points, and no study could be
included with fewer than 2 points (one for randomisation
and one for blinding). Study validity was assessed using a
validated 16-point scale [21].
Data were abstracted into a standard form. Information
extracted from the trials included details of the patients
(number, age, sex, pain syndrome), duloxetine dose, and
permitted rescue analgesia. The primary outcome sought
was 50% pain relief. Other measures of pain relief were
abstracted where reported. Secondary outcomes were
withdrawals (all cause, lack of efficacy and adverse events)
and adverse events (patients with at least one adverse
event, serious adverse events, and specific adverse events).
Guidelines for quality of reporting of meta-analyses were
followed where appropriate [22]. The prior intention was
to pool data where there was clinical and methodological
homogeneity, with similar patients, dose, duration, out-
comes, and comparators, but not where numbers of
events were small, and random chance might well domi-
nate effects of treatment [23]. Homogeneity tests and fun-
nel plots, though commonly used in meta-analysis, were
not used because they have been found to be unreliable
[24,25]. Instead, clinical homogeneity was examined
graphically [26]. Relative benefit (or risk) and number
needed to treat or harm (NNT or NNH) were calculated
with 95% confidence intervals. Relative benefit or risk was
calculated using a fixed effects model [27] with no statis-BMC Neurology 2008, 8:29 http://www.biomedcentral.com/1471-2377/8/29
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tically significant difference between treatments assumed
when the 95% confidence intervals included unity. We
added 0.5 to treatment and comparator arms of trials in
which at least one arm had no events. NNT or NNH was
calculated [28] using the pooled number of observations
only when there was a statistically significant difference of
relative benefit or risk (where the confidence interval did
not include 1). We used the following definitions:
• When significantly more beneficial outcomes occurred
with duloxetine than placebo, we used the term number
needed to treat (NNT).
￿ When significantly fewer adverse events occurred with
duloxetine than placebo we used the term the number-
needed-to-treat to prevent one adverse event (NNTp).
￿ When significantly more adverse events occurred with
duloxetine than placebo we used the term the number-
needed-to-harm to cause one adverse event (NNH).
Statistical significance of any difference between NNT for
different doses was assumed if there was no overlap of the
confidence intervals, and additionally tested using the z
statistic [29]. RevMan 5.0.12 was used to analyse continu-
ous data. There was a prior intention to carry out sensitiv-
ity analyses for high versus low trial quality (<3 vs ≥ 3)
and validity (<9 vs ≥ 9), duloxetine dose, and pain syn-
drome. A minimum of two trials and 250 patients was
required in any sensitivity analysis [23].
Results
We identified six trials satisfying the inclusion criteria [30-
35]. Details of the included studies are in Additional File
1. A total of 2,216 patients were included, 1,510 treated
with duloxetine and 706 with placebo. Three trials [32-
34] enrolled patients with PDN and three [30,31,35]
enrolled patients with fibromyalgia, in which 23% to 38%
had a diagnosis of major depressive disorder. The trials in
PDN excluded patients with any diagnosed psychological
disorder. We did not include any trials in which the pri-
mary problem was a major psychiatric disorder but with a
secondary painful condition [36-41]. All patients had
established baseline pain of at least moderate severity,
measured using established scales. The mean age in the
trials ranged between 49 and 61 years, and the majority of
patients were Caucasian. One trial [31] enrolled only
women, and the others between 5% and 61% men.
Trial duration was 12 to 13 weeks. One trial [33] had a 13-
week continuation phase, but results for the first 13 weeks
(acute phase) only are analysed here, to make it compara-
ble with the other trials. Duloxetine was used at doses of
20, 60, or 120 mg daily, with titration up to the 120 mg
dose, which was given as a divided dose of 60 mg twice
daily. Up to 2 g acetaminophen daily was permitted as res-
cue medication in the fibromyalgia trials, and up to 4 g
daily in the PDN trials.
Trials were of good methodological quality, with three
scoring 5/5, two scoring 4/5, and one scoring 3/5 on the
Oxford Quality Score [20]. Two scored 16/16 and four
scored 13/16 on the Oxford Pain Validity Score [21]. No




All six trials reported the outcome of at least 50% pain
relief over baseline in the 24-hour average pain score by
the end of the trial, and results are summarised in Figure
1 and Table 1. Trials were consistent, and overall 41% of
patients achieved 50% pain relief with any dose of duloxe-
tine compared with 24% with placebo. Combining all
doses in both conditions (2,216 patients), the NNT for
one patient to achieve at least 50% pain relief with
duloxetine compared with placebo was 5.9 (95% CI 4.8 to
7.7).
Five of the trials used 60 mg, and all six used 120 mg; only
66 patients (in two treatment arms) received the 20 mg
dose. The dose of duloxetine made little difference to the
result (Figure 1, Table 1). There was no difference in the
proportion of patients achieving at least 50% pain relief
with 60 mg and 120 mg (z = 0.13; p = 0.89).
There was no significant difference in the proportion of
patients achieving at least 50% pain relief with PDN or
fibromyalgia (z = 0.95; p = 0.34). The proportion of
patients with this outcome was slightly lower for both pla-
cebo and duloxetine groups in the fibromyalgia trials
(Table 1), with similar NNTs for both conditions.
Average pain score (APS)
Five of the trials [31-35] recorded daily 24-hour average
pain scores (APS) on a 0–10 scale, and reported this as a
weekly mean, as well as the change from baseline to final
weekly mean. The change in weekly mean APS on treat-
ment was compared with placebo over the 12 or 13 weeks.
Figure 2 shows the calculations for different doses of
duloxetine in different pain syndromes. The weighted
mean difference for duloxetine 60 mg compared with pla-
cebo was 1.0 (0.71 to 1.4), and for duloxetine 120 mg
compared with placebo was 0.9 (0.49 to 1.3). There was
no difference in response between patients with PDN and
fibromyalgia.
Withdrawals
Withdrawals for any cause occurred in slightly more
patients with duloxetine (30%) than placebo (28%); theBMC Neurology 2008, 8:29 http://www.biomedcentral.com/1471-2377/8/29
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NNTp for all cause withdrawal with duloxetine rather
than placebo was 26 (13 to 426) (Table 1). Withdrawals
due to lack of efficacy occurred in significantly fewer
patients (4%) taking duloxetine than placebo (9%); the
NNTp for lack of efficacy withdrawal with duloxetine
rather than placebo was 17 (12 to 35) (Table 1).
Withdrawals for any cause or for lack of efficacy did not
differ significantly between the 60 mg and 120 mg doses,
although for any cause they were consistently 4% to 5%
lower for 60 mg than 120 mg, except for Russell et al [35]
where the rates were almost identical.
Adverse events
Withdrawals
Withdrawals due to adverse events occurred significantly
more often with duloxetine (15%) than placebo (8%).
The NNH was 15 (11 to 25) (Table 1). They were 2% to
8% lower with 60 mg than 120 mg, giving an NNH of 19
(11 to 86) for 120 mg compared to 60 mg.
Any adverse event
The "at least one adverse event" criterion was met in sig-
nificantly more patients taking duloxetine (82%) than
placebo (67%) in the four trials that reported this out-
come. The NNH was 6.7 (5.0 to 10) (Table 1).
Serious adverse events
Serious adverse events were reported in only three trials;
one trial did not report this outcome [30], one did not
report it for the 13-week phase [35], and one did not sep-
arate rates between groups [32]. In the three trials report-
ing serious adverse events they were uncommon and not
significantly different between duloxetine or placebo, at
about 2–3% over the 12 weeks of the trials (Table 1). Rus-
sell et al [35] reported that serious adverse events were
infrequent over the full 6 months of the trial.
Specific adverse events
Only three trials [31,32,34] provided numbers of patients
experiencing specific treatment emergent adverse events
over 12 to 13 weeks. There were statistically significant
increases in nausea (29% vs 10%), somnolence (14% vs
4%), constipation (13% vs 3%) and decreased appetite
(7% vs 1%) with all doses of duloxetine compared with
placebo (Table 1). There were small mean increases in lab-
oratory tests and vital signs, but these were transient and
not considered clinically relevant by the trialists.
Discussion
This systematic review differs from the only other that
considers duloxetine [18]. That company-sponsored
review was able to pool data from the three PDN trials. It
Proportion of patients with at least 50% pain relief with duloxetine 60 mg or 120 mg and placebo in individual trials Figure 1
Proportion of patients with at least 50% pain relief with duloxetine 60 mg or 120 mg and placebo in individual trials. Pink circles 
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calculated NNTs for at least 50% pain relief (with identi-
cal results to those calculated here), and also gave NNTs
for at least 30% pain relief. It demonstrated the stability of
NNTs over two to 12 weeks, an important observation,
and no difference in estimate depending on treatment of
dropouts. This review differs in demonstrating that the
efficacy of duloxetine is similar in PDN and fibromyalgia,
and also makes an informed comparison with other evi-
dence on antidepressant treatments for neuropathic pain.
For evidence to be credible, it has to fulfil criteria of qual-
ity, validity, and size [42]. The evidence here on duloxet-
ine does that. Trials were randomised, and double blind,
and quality and validity scores indicated low chance of
bias. The trials were of sufficient length (12 or 13 weeks)
to make them clinically relevant, and the outcome
reported of at least 50% pain relief was a high hurdle.
Most older neuropathic pain studies used less stringent
measures, including undefined "improvement" as an out-
come, and only trials of pregabalin have also consistently
used at least 50% pain relief. Finally, with information on
over 2,200 patients, including over 1,000 patients with
PDN, the data set for duloxetine fulfils the requirements
of size [23] and is much larger than any previous data set
for antidepressants in neuropathic pain [13].
Significantly more patients achieved the outcome of at
least 50% pain relief with duloxetine (41%) than with
placebo (24%) over 12 weeks. The outcome of 50% pain
represents substantial clinical pain relief, and an NNT of 6
suggests that this is likely to be a useful drug in these dif-
ficult-to-treat conditions, where typically only a minority
of patients respond. There was no dose response between
60 mg and 120 mg, nor was there any significant differ-
ence in the duloxetine response between PDN or fibromy-
algia. There was a similar lack of dose response in this
range for use of duloxetine in major depressive disorder
[43].
Duloxetine was well tolerated in the trials, with fewer
withdrawals due to adverse events with 60 mg than with
120 mg. Most adverse events were reported to be mild or
moderate, with nausea, somnolence, constipation,
decreased appetite and dry mouth frequently mentioned.
In stress incontinence duloxetine affects the resting tone
and contraction of the urethral striated sphincter muscle.
It might be expected to cause symptoms of urinary hesi-
tancy in patients without incontinence, but urinary prob-
lems were not reported in any of these trials, or in trials of
duloxetine in depression [for example [44,45]].
This review has some limitations. Firstly, pain intensity
measurements used to calculate our primary outcome of
at least 50% pain relief were derived from average pain
intensity scores during the previous 24 hours. Secondly,
the trials were 12 to 13 weeks in duration, and although
they demonstrated a sustained response and good tolera-
bility over this period, they provided no information for
longer-term efficacy or safety. Russell et al [35] included a
13-week continuation phase, and reported continuing
Table 1: Summary of efficacy and adverse event outcomes in duloxetine trials
Number of Percent with
Outcome Dose 
(daily maximum)





50% PR All 20/60/120 mg 6 2,216 41 24 1.7 (1.4 to 1.9) 5.9 (4.8 to 7.7)
50% PR PDN 60/120 mg 3 1,024 47 27 1.7 (1.4 to 2.1) 5.1 (3.9 to 7.3)
50% PR fibromyalgia 60/120 mg 3 996 37 21 1.7 (1.4 to 2.1) 6.4 (4.7 to 9.9)
50% PR 60 mg 5 1,211 43 26 1.7 (1.4 to 2.0) 5.8 (4.4 to 8.4)
50% PR 120 mg 6 1,410 42 24 1.7 (1.5 to 2.0) 5.7 (4.5 to 7.8)
Adverse events general
Withdrawal – all cause 20/60/120 mg 6 2,418 30 26 1.2 (1.1 to 1.4) 26 (13 to 426)
Withdrawal – LoE 20/60/120 mg 5 1,872 4 9 0.5 (0.4 to 0.7) 20 (13 to 42)
Withdrawal – AE 20/60/120 mg 6 2,220 15 8 1.8 (1.4 to 2.4) 15 (11 to 25)
Any AE 60/120 mg 4 1,243 82 67 1.2 (1.2 to 1.3) 6.7 (5.0 to 10)
Serious AE 60/120 mg 3 1,034 2 3 0.8 (0.4 to 1.7) not calculated
Specific adverse events
Nausea 20/60/120 mg 3 1,145 29 10 3.0 (2.2 to 4.3) 5.3 (4.3 to 6.9)
Somnolence 20/60/120 mg 3 1,145 14 4 2.9 (1.7 to 4.9) 11 (8.0 to 16)
Constipation 20/60/120 mg 3 1,145 13 3 3.6 (2.0 to 6.5) 11 (8.3 to 16)
Decreased appetite 20/60/120 mg 2 811 7 1 4.9 (1.7 to 14) 18 (12 to 34)
PR – pain relief; PDN – painful diabetic neuropathy; LoE – lack of efficacy; AE – adverse event
In the right hand column, bold font is used for NNT – number needed to treat; normal font for NNTp – number need to treat to prevent; italic 
font for NNH – number needed to harmBMC Neurology 2008, 8:29 http://www.biomedcentral.com/1471-2377/8/29
Page 6 of 9
(page number not for citation purposes)
efficacy and tolerability, as have open-label extension
studies in neuropathic pain lasting 26 and 52 weeks
[46,47].
Duloxetine has been widely trialled in other conditions,
in particular depression and stress-induced incontinence
in women, and the many trials have been subject to sys-
tematic review in those therapeutic areas. An evaluation of
cardiovascular safety in 42 placebo controlled trials
involving 8,500 patients concluded that duloxetine did
not appear to be associated with significant cardiovascular
risks [48].
Finally, the studies in fibromyalgia included some
patients with depression. Although only a minority were
depressed (Additional file 1), it could be argued that
duloxetine reduced pain intensity by improving depres-
sion. We identified a small number of other trials in
patients with psychiatric disorders with painful physical
symptoms (not neuropathic pain) [36-41]. Although
none reported our primary outcome of 50% pain relief,
they did use the same scales to record pain intensity, and
all reported improvements in pain with duloxetine 60 mg
that did not entirely correlate with improvements in
depression. Fava et al. estimated that 50% of the total
effect of duloxetine on overall pain was independent of
changes in depression [37]. A counter view was that
duloxetine was ineffective in treating pain in depression
[49]. In the trials included in this review, about one third
of the patients with fibromyalgia also had major depres-
sive disorder. It would be difficult to attribute all of the
analgesic effect of duloxetine in these trials to improve-
ments in depression in a minority, although one could
not rule out a contributory effect. One of these trials esti-
mated that around 20% of the overall treatment effect
with 120 mg and 30% with 60 mg was due to improve-
ments in depressive symptoms, the remainder being due
to duloxetine's direct effect on pain reduction [35].
Mean change from baseline to endpoint on the 24-hour average pain score (APS) for treatment compared to placebo over 12  to 13 weeks, by duloxetine dose (60 mg and 120 mg) and condition (diabetic neuropathy and fibromyalgia) Figure 2
Mean change from baseline to endpoint on the 24-hour average pain score (APS) for treatment compared to placebo over 12 
to 13 weeks, by duloxetine dose (60 mg and 120 mg) and condition (diabetic neuropathy and fibromyalgia).BMC Neurology 2008, 8:29 http://www.biomedcentral.com/1471-2377/8/29
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The quantity and quality of randomised trial data in neu-
ropathic pain is limited. Table 2 shows the results for
duloxetine 60 mg and 120 mg over 12 weeks compared
with other results for antidepressants calculated from a
recent Cochrane review [13]. Only patients with PDN are
reported in Table 2 for duloxetine, in order to keep to sim-
ilar inclusion criteria. Even so, the amount of evidence on
duloxetine dominates the evidence available, almost dou-
bling the number of patients studied previously with anti-
depressants. Table 2 shows the curious tendency for
smaller amounts of information to be associated with
greater benefit, either as higher values for relative risk or
lower values for NNT. Size and quality may be linked:
only one trial in the Cochrane meta-analysis had over 100
participants, while all the duloxetine trials had over 200,
and many older studies used poorly defined outcomes of
improvement, probably less stringent than that of at least
50% pain relief. Some small older studies also had a cross-
over rather than parallel design. This presents problems in
determining relative efficacy among antidepressants for
treatment of neuropathic pain.
Several evidence-based recommendations for the treat-
ment of neuropathic pain place use of antidepressants
early in any care pathway [5,9,50]. Comparing the evi-
dence for different therapies within a class, and between
classes, is key to determining the most effective, and most
cost-effective pathway. In that circumstance, it is not
enough just to calculate an NNT. The quality and credibil-
ity of the evidence behind those calculations needs to be
evaluated, a function of the utility and validity of out-
comes, and to have sufficient numbers of patients or
events to avoid random chance. The example of duloxet-
ine provides a firm evidential base for within and between
class comparisons.
Conclusion
Duloxetine is equally effective for the treatment of PDN
and fibromyalgia, judged by the outcome of at least 50%
pain relief over 12 to 13 weeks, and is well tolerated. The
NNT of 6 for this outcome suggests that this is likely to be
a useful drug in these difficult-to-treat conditions, where
typically only a minority of patients respond. Doses
higher than 60 mg do not provide additional pain relief,
but do cause slightly more withdrawals due to adverse
events. Comparing duloxetine with other antidepressants
for pain relief in PDN shows inadequacies in the evidence
for efficacy of antidepressants, which are currently recom-
mended in PDN care pathways.
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